Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Sanofi”

Pooled Analysis of Methodologically Harmonized Pragmatic Randomized Trials of High-Dose vs. Standard-Dose Influenza Vaccine Against Severe Clinical OutcomesCompleted
NCT06506812Phase 4Updated Sep 12, 2025
Sponsor: Tor Biering-Sørensen
Influenza
Denmark
Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2020-2021 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, RespectivelyCompleted
NCT04551677Phase 4Updated Sep 12, 2025
Sponsor: Sanofi Pasteur, a Sanofi Company
Influenza Immunization · Healthy Volunteers
United States
Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or Singly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 VaccineCompleted
NCT04969276Phase 2Updated Sep 12, 2025
Sponsor: Sanofi Pasteur, a Sanofi Company
Influenza Immunization · Healthy Volunteers
United States
Study to Evaluate the Immune Response After Booster Vaccination With Tdap-IPV Vaccine (Against Tetanus, Diphtheria, Pertussis and Poliomyelitis) in Children Who Received Different Pertussis Primary Vaccine Regimens in Republic of South AfricaCompleted
NCT04300192Phase 4Updated Sep 12, 2025
Sponsor: Sanofi Pasteur, a Sanofi Company
Pertussis Immunisation · Diphtheria Immunisation · Tetanus Immunisation · Poliomyelitis Vaccine
South Africa
Dupilumab in Japanese Patients With Atopic DermatitisCompleted
NCT04678882Phase 3Updated Sep 12, 2025
Sponsor: Sanofi
Atopic Dermatitis
Japan
First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple MyelomaCompleted
NCT04000282Phase 1Updated Sep 12, 2025
Sponsor: Sanofi
Plasma Cell Myeloma
United States, Czechia, France, Greece, Spain +1 more
Substudy 01 - Safety and Immunogenicity of One Monovalent Modified mRNA Vaccine Encoding Influenza Hemagglutinin With LNP, in Adult Participants Aged 18 to 49 Years and 60 Years and AboveCompleted
NCT05829356Phase 1Updated Sep 12, 2025
Sponsor: Sanofi Pasteur, a Sanofi Company
Influenza Immunization
Australia, United Kingdom
Bioavailability Study of Magne-B6 New FormulationCompleted
NCT06386211Phase 1Updated Sep 12, 2025
Sponsor: Opella Healthcare Group SAS, a Sanofi Company
Healthy Volunteers
Turkey (Türkiye)
Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Europeans Adults 60 Years of Age and OlderCompleted
NCT04024228Phase 3Updated Sep 12, 2025
Sponsor: Sanofi Pasteur, a Sanofi Company
Influenza Immunization · Healthy Volunteers
Belgium, France, Germany, Italy, Netherlands +1 more
A Pragmatic Randomized Trial to Evaluate the Effectiveness of High-Dose Quadrivalent Influenza Vaccine vs. Standard-Dose Quadrivalent Influenza Vaccine in Older AdultsCompleted
NCT05517174Phase 4Updated Sep 12, 2025
Sponsor: Tor Biering-Sørensen
Influenza
Denmark
Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, RespectivelyCompleted
NCT04109222Phase 4Updated Sep 12, 2025
Sponsor: Sanofi Pasteur, a Sanofi Company
Influenza
United States
Safety, Efficacy and PK of BIVV001 in Pediatric Patients With Hemophilia ACompleted
NCT04759131Phase 3Updated Sep 11, 2025
Sponsor: Bioverativ, a Sanofi company
Hemophilia A
United States, Australia, Canada, France, Germany +10 more
Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine in Older Adults Who Received a Primary Vaccination (3 or More Years Earlier) in Study MET49Completed
NCT04142242Phase 3Updated Sep 11, 2025
Sponsor: Sanofi Pasteur, a Sanofi Company
Meningococcal Infection (Healthy Volunteers)
United States, Puerto Rico
Single Ascending Dose Study of SAR439459 in Adults With Osteogenesis Imperfecta (OI)Terminated
NCT05231668Phase 1Updated Sep 11, 2025
Sponsor: Sanofi
Osteogenesis Imperfecta
United States, Australia, Canada, France
Dupilumab in Japanese Patients With Chronic Rhinosinusitis With Nasal Polyp (SINUS-M52)Completed
NCT05049122Phase 4Updated Sep 11, 2025
Sponsor: Sanofi
Chronic Rhinosinusitis With Nasal Polyps
Japan
Safety and Tolerability Study in Adults With Cold Agglutinin Disease Previously Treated With SAR445088 or Never Treated With SAR445088Terminated
NCT04802057Phase 1Updated Sep 11, 2025
Sponsor: Bioverativ, a Sanofi company
Autoimmune Haemolytic Anaemia
Germany, Italy, Netherlands, Norway, United Kingdom
Study of mRNA Vaccine Formulation Against COVID-19 in Healthy Adults 18 Years of Age and OlderTerminated
NCT04798027Phase 1, Phase 2Updated Sep 11, 2025
Sponsor: Sanofi Pasteur, a Sanofi Company
COVID-19
United States, Australia, Brazil, Honduras
Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast CancerTerminated
NCT04478266Phase 3Updated Sep 11, 2025
Sponsor: Sanofi
Breast Cancer
United States, Argentina, Australia, Austria, Belgium +25 more
China Post-marketing Surveillance (PMS) Study of Fabrazyme®Completed
NCT05054387Phase 4Updated Sep 11, 2025
Sponsor: Genzyme, a Sanofi Company
Fabry Disease
China
Study of Lademirsen (SAR339375) in Patients With Alport SyndromeTerminated
NCT02855268Phase 2Updated Sep 11, 2025
Sponsor: Genzyme, a Sanofi Company
Alport Syndrome
United States, Australia, China, France, Germany +2 more
Study of Influenza Vaccines Containing an Additional H3 Antigen in Healthy Adult Participants 18 to 49 Years of Age and 60 Years of Age and OlderCompleted
NCT06507553Phase 1Updated Sep 11, 2025
Sponsor: Sanofi Pasteur, a Sanofi Company
Influenza · Healthy Volunteers
Australia
Study of the Safety and Immune Response of an Investigational mRNA Vaccine for the Prevention of Respiratory Syncytial Virus and/or Human Metapneumovirus in Participants Aged 18 to 49 Years and 60 Years and OlderCompleted
NCT06237296Phase 1Updated Sep 11, 2025
Sponsor: Sanofi Pasteur, a Sanofi Company
Respiratory Syncytial Virus Infection · Healthy Volunteers · Metapneumovirus Infection
United States, Australia
Study Describing the Immunogenicity and Safety of Quadrivalent Recombinant Influenza Vaccine (RIV4) Versus a Licensed Quadrivalent-inactivated Influenza Vaccine (IIV4) (Fluarix® Quadrivalent) in Participants 18 Years of Age and Older in South KoreaCompleted
NCT05144945Phase 3Updated Sep 11, 2025
Sponsor: Sanofi Pasteur, a Sanofi Company
Influenza (Healthy Volunteers)
South Korea
First-in-human Study of SAR443765 in Healthy Participants and in Asthmatic ParticipantsCompleted
NCT05366764Phase 1Updated Sep 10, 2025
Sponsor: Sanofi
Asthma
Germany, United Kingdom
Concomitant Chemo-radiotherapy in Locally Advanced Non Small Cell Lung CancerWithdrawn
NCT00210171Phase 2Updated Sep 10, 2025
Sponsor: Institut Bergonié
Carcinoma, Non-Small-Cell Lung
France

Previous page Next page